|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | National Institute on Aging (NIA) |
|---|---|
| Information provided by: | National Institute on Aging (NIA) |
| ClinicalTrials.gov Identifier: | NCT00315575 |
Purpose
The purpose of this study is to develop imaging techniques that can distinguish functional brain changes in people at high risk for dementia years prior to onset of clinical memory problems from those with normal changes of aging.
| Condition | Intervention |
|---|---|
|
Alzheimer's Disease |
Procedure: BOLD and Perfusion brain MRI |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Cross-Sectional |
| Official Title: | BOLD and Perfusion fMRI of Alzheimer's Disease Risk |
| Estimated Enrollment: | 90 |
| Study Start Date: | August 2005 |
| Study Completion Date: | July 2008 |
| Primary Completion Date: | July 2008 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
1
Individuals with high risk for Alzheimer's disease
|
Procedure: BOLD and Perfusion brain MRI
Blood oxygenation and perfusion functional MRI performed twice, two weeks apart; each scan lasts 1 hour
|
|
2
Individuals with low risk for Alzheimer's disease
|
Procedure: BOLD and Perfusion brain MRI
Blood oxygenation and perfusion functional MRI performed twice, two weeks apart; each scan lasts 1 hour
|
The overall goals of this project are to identify consistent patterns of variance in brain function in patients at risk for Alzheimer's Disease by using APOE ε4 as a marker for disease risk. The activation Blood Oxygen Level Dependency (BOLD) signal will be compared to both resting and activation perfusion signals to assess the variability of cerebral blood flow as it relates to the BOLD signal. Each participant will be imaged on a 3T MRI scanner while performing an associate episodic memory task.
A total of 90 individuals will be recruited for this study. Participants will be non-demented, right handed, adults with or without at least one APOE ε4 allele. Groups will be split as follows: A) ages 25-39: non-ε4 (n=15); B) ages 25-39: +ε4 (n=15); C) ages 40-49: non-ε4 (n=15); D) ages 40-49: +ε4 (n=15);.E) ages 50-65: non-ε4: F) ages 50-65: +ε4 (n=15). These groups will be matched for mean age, mean years of education, gender distribution, as well as the presence or absence of a family history of AD in a first degree relative.
There will be 2 scanning sessions for each participant. Scan session #1 and Scan session #2 will be acquired within 2 weeks of each other and will take approximately one hour each.
Eligibility| Ages Eligible for Study: | 25 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
healthy adults from the community
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, California | |
| Shiley-Marcos Alzheimer's Disease Research Center, University of California, San Diego | |
| La Jolla, California, United States, 92037 | |
| Principal Investigator: | Adam Fleisher, MD | University of California, San Diego |
More Information
| Responsible Party: | Adam Fleisher, MD, University of California, San Diego |
| ClinicalTrials.gov Identifier: | NCT00315575 History of Changes |
| Other Study ID Numbers: | IA0092, 5K23AG024062-02 |
| Study First Received: | April 14, 2006 |
| Last Updated: | January 22, 2009 |
| Health Authority: | United States: Federal Government |
|
Dementia brain circulation disease /disorder proneness /risk neuropathology neurophysiology aging |
apolipoprotein E genotype hemodynamics memory temporal lobe /cortex |
|
Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases |
Tauopathies Neurodegenerative Diseases Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders |